The UK’s cost-effectiveness watchdog National Institute of Health and Clinical Excellence (NICE) has delivered another blow to the developers of targeted cancer therapies by recommending against the use of four new kidney cancer drugs in the UK. This recommendation suggests that NICE is likely to look unfavorably on a number of other targeted therapies in development, severely limiting future growth of the targeted cancer therapies market in the UK.
Continue reading “UK Watchdog NICE Turns Down Four New Kidney Cancer Drugs” »


